Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BY 4.0Molecules

PCSK6 in Pathophysiology and Its Potential Involvement in Pulmonary Fibrosis

  • Qian Tian1,2
  • C. Arnold Spek3,4
  • Jan Willem Duitman1,2,5
5 affiliations
  1. 1Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
  2. 2Amsterdam Institute of Immunology & Infectious Disease, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
  3. 3Center for Infection and Molecular Medicine, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
  4. 4Laboratory of Experimental Oncology and Radiobiology, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
  5. 5Department of Pulmonary Medicine, Amsterdam UMC Location University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
Open at sourceDOICite

Abstract

Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a proteolytic enzyme that may act on a broad spectrum of substrates, including growth factors, extracellular proteases, adhesion molecules, protease activated receptor 1, the prorenin receptor, and Corin. As a consequence of its broad-spectrum substrate activity, PCSK6 is implicated in a wide range of pathophysiological processes such as cardiovascular disease, neurological disorders, arthritis and cancer. Of special interest, PCSK6 has recently been shown to be highly expressed in patients with idiopathic pulmonary fibrosis (IPF) and PCSK6 has been associated with reduced survival of IPF patients, linking PCSK6 to pulmonary fibrosis for the first time. Of note however, PCSK6 levels in plasma were not associated with respiratory outcomes in IPF patients and higher PCSK6 levels were even associated with a lower hazard of 10% FVC decline in non-IPF ILD patients. In this review, we summarize the molecular biology of PCSK6, including its structural features and its major (potential) substrates, and outline its pathophysiological roles across various diseases. Furthermore, we propose and discuss the potential involvement of PCSK6 in pulmonary fibrosis to guide future research.

Related

  1. Integrative network toxicology and machine learning reveal the potential role of 5-hydroxymethylfurfural in exacerbating pulmonary fibrosis
    Qinghuan Yang, Fuli Li, Jiani Li +1
    PLOS OnePeer-reviewedCC BYFull textMolecular biology & gene regulationDevelopmental biologyPLOSEurope PMCPMC
  2. The Emulsifying Properties of Rice-Based Fermented Foods: Contribution of the Insoluble Fraction with Potential Protein Involvement
    Kazuya Kobayashi, Moemi Anada, Wataru Noro +6
    Journal of Oleo SciencePeer-reviewedLicence not statedFull textGeneral chemistryJ-STAGE
  3. Effects of a Benzimidazolium Salt on Colorectal Cancer Cells: Involvement of Apoptosis and Autophagy
    Mustafa Cakir, Eda Acikgoz, Burak Kuzu +4
    MoleculesPeer-reviewedCC BY 4.0Full textOrganic chemistryCrossrefEurope PMC
  4. Multifunctional Nanomedicine for Precision Theranostics in Hepatic Fibrosis: From Rational Design to Clinical Translation.
    Yanan Li, Yanjiao Gong, Xinze Li +6
    International journal of nanomedicinePeer-reviewedCC BY-NCFull textMaterials & polymersEurope PMCPMC
  5. Chemically programmable hybrid membrane-camouflaged acetate gossypol prodrug reprograms the hepatic microenvironment for the treatment of liver fibrosis
    Mingming Song, Ying Fang, Xiaqing Gong +5
    Journal of NanobiotechnologyPeer-reviewedCC BY-NC-ND 4.0Full textMaterials & polymersPMCDOAJ

Cite

BibTeXRIS
BibTeX
@article{tian2026pcsk6,
  title = {{PCSK6 in Pathophysiology and Its Potential Involvement in Pulmonary Fibrosis}},
  author = {Qian Tian and C. Arnold Spek and Jan Willem Duitman},
  journal = {Molecules},
  year = {2026},
  month = nov,
  doi = {10.3390/molecules31213931},
  url = {https://www.mdpi.com/1420-3049/31/21/3931},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - PCSK6 in Pathophysiology and Its Potential Involvement in Pulmonary Fibrosis
AU  - Qian Tian
AU  - C. Arnold Spek
AU  - Jan Willem Duitman
PY  - 2026
DA  - 2026/11/01
JO  - Molecules
DO  - 10.3390/molecules31213931
UR  - https://www.mdpi.com/1420-3049/31/21/3931
AB  - Proprotein convertase subtilisin/kexin type 6 (PCSK6) is a proteolytic enzyme that may act on a broad spectrum of substrates, including growth factors, extracellular proteases, adhesion molecules, protease activated receptor 1, the prorenin receptor, and Corin. As a consequence of its broad-spectrum substrate activity, PCSK6 is implicated in a wide range of pathophysiological processes such as cardiovascular disease, neurological disorders, arthritis and cancer. Of special interest, PCSK6 has recently been shown to be highly expressed in patients with idiopathic pulmonary fibrosis (IPF) and PCSK6 has been associated with reduced survival of IPF patients, linking PCSK6 to pulmonary fibrosis for the first time. Of note however, PCSK6 levels in plasma were not associated with respiratory outcomes in IPF patients and higher PCSK6 levels were even associated with a lower hazard of 10% FVC decline in non-IPF ILD patients. In this review, we summarize the molecular biology of PCSK6, including its structural features and its major (potential) substrates, and outline its pathophysiological roles across various diseases. Furthermore, we propose and discuss the potential involvement of PCSK6 in pulmonary fibrosis to guide future research.
SN  - 1420-3049
ER  -